Conclusion: The perioperative management of patients taking incretinbased therapies (GLP1 and GIP receptor agonists) and SGLT2 inhibitors is evolving as these drugs gain widespread use for diabetes, obesity, and cardiorenal protection
Because discontinuing Tirzepatide often results in weight regain, we typically recommend ongoing therapy unless you experience side effects, insufficient results, or other health concerns
For many, a lower, consistent dose of a highly bioavailable formula is sufficient to maintain steady levels
A multidomain program combining regular physical activity, a healthy dietary pattern, cardiometabolic health monitoring (blood pressure, blood sugar, cholesterol), and cognitive and social engagement produced measurable cognitive protection over two years in a diverse population of at-risk older Americans equivalent to roughly two years of cognitive advantage compared to a less structured approach